SCHEMBL30136050

SCHEMBL30136050

O=C(NC1CCN(C(=O)CC2CCNC2)CC1)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.52
▸ GAA P10253 1/20 0.52
▸ CTSL P07711 1/20 0.51
▸ CTSB P07858 1/20 0.51
▸ CTSK P43235 1/20 0.51
▸ TSHR P16473 1/20 0.50
▸ DPP4 P27487 7/20 0.49
▸ DPP7 Q9UHL4 7/20 0.49
▸ KCNH2 Q12809 4/20 0.49
▸ HSD11B1 P28845 1/20 0.49
▸ EPHX1 P07099 1/20 0.47
▸ TGM2 P21980 2/20 0.46
▸ F13A1 P00488 1/20 0.44
▸ TGM1 P22735 1/20 0.44
▸ TPSAB1 Q15661 1/20 0.44
▸ TPSD1 Q9BZJ3 1/20 0.44
▸ TPSG1 Q9NRR2 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ GPR55 Q9Y2T6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135921 0.94 ALDH1A1 (0.54) ALDH1A1GAACTSLCTSBCTSK
SCHEMBL30981191 0.85 ITGB3 (0.56) ALDH1A1GAACTSLCTSBCTSK
SCHEMBL30981171 0.85 ALDH1A1 (0.54) ALDH1A1GAACTSLCTSBCTSK
SCHEMBL240038 0.79 ALDH1A1 (0.63) ALDH1A1GAACTSLCTSBCTSK
SCHEMBL2901586 0.79 ALDH1A1 (0.63) ALDH1A1GAACTSLCTSBCTSK
SCHEMBL240039 0.79 ALDH1A1 (0.63) ALDH1A1GAACTSLCTSBCTSK
SCHEMBL1870932 0.79 ALDH1A1 (0.67) ALDH1A1GAACTSLCTSBCTSK
SCHEMBL25935100 0.79 ALDH1A1 (0.57) ALDH1A1GAACTSLCTSBCTSK
SCHEMBL7617 0.79 ALDH1A1 (0.70) ALDH1A1GAACTSLCTSBCTSK
SCHEMBL30136006 0.79 TSHR (0.60) ALDH1A1GAACTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-04-10 — — US disclosed
EP-4384520-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 — — EP disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 — — WO disclosed
WO-2023017442-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ALDH1A1 4008/4885GAA 2658/4885CTSL 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback